Panelists discuss the importance of using liquid biopsy for detecting estrogen receptor 1 (ESR1) mutations rather than relying on archival tissue testing.

Panelists discuss how molecular testing and liquid biopsies are crucial for tracking estrogen receptor 1 (ESR1) mutations in patients with metastatic breast cancer, particularly as a mechanism of resistance to aromatase inhibitor treatment.

CT0596 was well tolerated and showed preliminary efficacy in relapsed/refractory multiple myeloma, early phase 1 data show.

The agent is currently being evaluated as both monotherapy and in combination with atezolizumab in patients with extensive stage SCLC in an ongoing, global phase 1 trial.

Oncology nurses can help advocate for AI-assisted diagnostic improvements.

The combo showed safety and efficacy in patients with c-MET protein overexpression who progressed on prior osimertinib.

Neoadjuvant ribociclib plus endocrine therapy showed pCR rates comparable to chemo in HR-positive, HER2-negative early breast cancer.

Disitamab vedotin plus toripalimab improved PFS and OS over chemo in HER2+ metastatic urothelial cancer, per phase 3 RC48-C016 interim analysis.

Disitamab vedotin with toripalimab improved PFS and OS over chemo in HER2-expressing metastatic urothelial carcinoma, per phase 3 trial interim analysis.

The amount of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to personalize treatment.

Three of 18 patients had remissions lasting over 2 years in a study of ibrutinib plus nivolumab for relapsed/refractory CNS lymphoma.

Retifanlimab has received approval for the frontline treatment of advanced anal cancer from the FDA.

The extended injection time for subcutaneous daratumumab in those with myeloma can serve as an opportunity for oncology nurses to check in with patients.

The addition of bevacizumab to capecitabine produced favorable efficacy and safety data for older patients with metastatic colorectal cancer.

Panelists discuss how managing common adverse events associated with tyrosine kinase inhibitors (TKIs) such as nilotinib requires proactive strategies including supportive medications, dose adjustments, monitoring for gastrointestinal (GI) symptoms, rashes, elevated liver enzymes and glucose metabolism changes, and encouraging patients to maintain ongoing care with their primary care providers for comorbid conditions that could exacerbate potential cardiovascular risks.

Panelists discuss how simpler treatment regimens with fewer restrictions, such as the new nilotinib formulation without fasting requirements, can improve the chronic myeloid leukemia (CML) management approach by making medication adherence easier for patients, while acknowledging that even with improved formulations, all drugs still have potential adverse effects that require ongoing education and support, particularly for patients who may need lifelong therapy rather than achieving treatment-free remission.

Telisotuzumab vedotin-tllv has earned accelerated approval for use in patients with non-squamous non-small cell lung cancer with high c-Met overexpression.

Belzutifan has become the first FDA-approved oral therapy for pheochromocytoma or paraganglioma.

The phase 2b SURVIVE trial of SurVaxM in newly diagnosed glioblastoma will continue as planned following an interim review by an independent safety board.

T-DXd followed by THP improved pCR in high-risk, early-stage HER2+ breast cancer in the phase 3 DESTINY-Breast11 trial.

ADRX-0706 has received FDA fast track designation for the treatment of metastatic or locally advanced squamous cell cervical cancer.

Treatment-related adverse effects were reported in 97.2% of heavily pretreated patients with uterine serous carcinoma taking adavosertib.

Infusion bays designed with nurse input provide patients the choice between privacy and community while allowing support from loved ones.

The safety and efficacy of givinostat is being assessed vs hydroxyurea in the phase 3 GIV-IN PV trial.

Oncology nurses can enhance endometrial cancer recovery by fostering strong social support networks and improving communication.